Dr. Wendy Dixon is the Director for Black Diamond Therapeutics. She previously served as a Director of Alkermes, Ardea
Biosciences, Bluebird bio, Dentsply International, Furiex Pharmaceuticals, Incyte, Iovance Biotherapeutics, Orexigen Therapeutics, Sesen Bio, and Voyager Therapeutics. Additionally, she served as an Independent Director for Edimer Therapeutics, a private company. From 2001 to 2009, Dr. Dixon was Chief Marketing Officer & President of Global Marketing at Bristol Myers Squibb, as well as a member of the CEO’s Executive Committee. Prior to this she served as Senior Vice President of Marketing for Merck & Co., Inc. Dr. Dixon also held senior vice president roles at West Pharmaceuticals, Osteotech, Inc., Centocor, Inc., and Smith Kline & French Pharmaceuticals.
Throughout her career in the pharmaceutical and biotechnology industries, Dr. Dixon has been responsible for building and leading organizations, and launching and growing more than 20 pharmaceutical products, including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge, UK.